Zydus Lifesciences has secured final USFDA approval and 180-day CGT exclusivity for Ascorbic Acid Injection USP in 25,000 mg/50 mL and 5,000 mg/10 mL strengths. Produced at Jarod, Gujarat, the generic alternative to Ascor treats acute scurvy in institutional settings, targeting a $11.6 million U.S. hospital market.
AHMEDABAD, India — Indian pharmaceutical manufacturer Zydus Lifesciences Limited announced on Friday, August 21, 2026, that it has secured final approval from the United States Food and Drug Administration (USFDA) for its generic Ascorbic Acid Injection USP. The regulatory decision includes eligibility for 180 days of Competitive Generic Therapy (CGT) exclusivity, enabling the drugmaker to launch the first generic alternative to the reference listed drug and address persistent institutional demand across U.S. clinical healthcare networks.
USFDA Approval Details and 180-Day Market Exclusivity
According to a regulatory filing submitted to Indian stock exchanges, the USFDA cleared Zydus’ Abbreviated New Drug Application (ANDA) for Ascorbic Acid Injection USP in two distinct concentration presentations: 25,000 mg/50 mL (500 mg/mL) and 5,000 mg/10 mL (500 mg/mL).
The drug is the generic equivalent of the reference listed drug (RLD), Ascor Injection (25,000 mg/50 mL), marketed by McGuff Pharmaceuticals, Inc.
Under the USFDA's Competitive Generic Therapy pathway, established under the FDA Reauthorization Act of 2017 to incentivize generic development for drugs with limited commercial competition, Zydus has been designated as an eligible first approved applicant. The 180-day generic marketing exclusivity begins on the first day of commercial distribution in the United States, during which the agency will generally not grant final approval to competing generic applications for the identical product.
The injectable formulation will be manufactured at Zydus Lifesciences’ dedicated sterile injectables manufacturing facility located at Jarod, near Vadodara in Gujarat, India. Commercial marketing and hospital distribution across the United States will be managed by the company’s wholly owned subsidiary, Zydus Pharmaceuticals (USA) Inc.
Clinical Indications and Institutional Applications
Ascorbic Acid Injection USP is a sterile solution of therapeutic-grade vitamin C formulated for intravenous, intramuscular, or subcutaneous administration. According to the approved prescribing information, the formulation is indicated primarily for the short-term treatment of scurvy in adult and pediatric patients aged 5 months and older when oral nutritional intake is not possible, insufficient, or clinically contraindicated.
In hospital settings, acute ascorbic acid deficiency is encountered among patients suffering from severe gastrointestinal malabsorption, extensive thermal burn injuries, chronic dialysis, trauma, and major surgical resections. Because oral supplementation cannot achieve immediate systemic bioavailability in patients with impaired bowel function, intravenous ascorbic acid serves as an indispensable hospital intervention to prevent severe metabolic decompensation, collagen breakdown, and capillary fragility.
Commercial Valuation and Generic Pipeline Footprint
The branded formulation of Ascor Injection recorded annual sales of approximately $11.6 million in the United States for the 12-month period ending June 2026, according to pharmaceutical data provider IQVIA MAT.
While the absolute market size remains concentrated, the CGT exclusivity status guarantees an advantageous pricing window and direct procurement agreements with major U.S. hospital group purchasing organizations (GPOs).
The clearance marks another addition to Zydus Lifesciences’ growing presence in complex sterile injectables. Following this clearance, the Zydus Group holds 448 cumulative ANDA approvals from the USFDA out of 513 total applications filed since initiating its U.S. regulatory filing program in the 2003–04 fiscal year.
Impact on Healthcare Systems and Institutional Buyers
The arrival of a generic ascorbic acid injection provides substantial relief to institutional supply chains:
Healthcare Providers: Hospitals and intensive care units gain a dependable generic supply source for critical nutritional support, mitigating vulnerability to single-manufacturer production disruptions.
Institutional Payers: Generic competition is projected to lower unit procurement costs for inpatient pharmacy formularies and ambulatory infusion suites.
Investors and Industry Analysts: The 180-day exclusivity structure provides Zydus with protected commercial margins throughout the initial half-year of market rollout.
Official Sources
The development was verified through formal disclosures published across regulatory and market surveillance platforms:
Official Statements
According to regulatory disclosures submitted by the company's executive secretariat:
"The receipt of final approval from the USFDA for Ascorbic Acid Injection with 180-day CGT exclusivity reflects our ongoing commitment to strengthening our complex injectable portfolio and addressing critical drug supply requirements for healthcare providers in the United States."
Why It Matters
Injectable generic therapies that enter the market via the CGT pathway resolve severe supply bottlenecks in hospital-grade formulations. For critical care clinics and clinical nutrition specialists, this approval delivers an FDA-certified, competitively priced sterile alternative for patients with acute micronutrient depletion, while cementing Zydus' capacity to supply high-barrier parenteral therapies.
Key Facts at a Glance
Drug Name: Ascorbic Acid Injection USP (Generic equivalent to Ascor).
Dosage Strengths: 25,000 mg/50 mL (500 mg/mL) and 5,000 mg/10 mL (500 mg/mL).
Regulatory Incentive: 180-day Competitive Generic Therapy (CGT) exclusivity.
Approved Indication: Short-term scurvy treatment in adults and children aged 5 months and older unable to receive oral therapy.
Manufacturing Hub: Sterile injectables facility at Jarod, Vadodara, Gujarat.
U.S. Market Volume: Brand sales reached approximately $11.6 million as of June 2026 (IQVIA MAT).
Frequently Asked Questions
What is the purpose of Ascorbic Acid Injection in hospital settings?
Ascorbic Acid Injection delivers high-dose vitamin C intravenously, subcutaneously, or intramuscularly to treat scurvy and severe micronutrient deficiencies in patients who cannot tolerate or absorb oral supplements.
What does 180-day CGT exclusivity mean for Zydus Lifesciences?
The Competitive Generic Therapy designation grants Zydus a 180-day commercial marketing window starting from product launch, during which the USFDA generally will not approve competing generic applications for the same formulation.
Which age group is cleared to receive this generic injection?
Under approved USFDA prescribing guidelines, the injection is indicated for adult patients as well as pediatric patients aged five months and older.
Where is the product produced and distributed?
The drug will be manufactured at Zydus Lifesciences’ Jarod plant in Vadodara, Gujarat, and distributed throughout the United States by Zydus Pharmaceuticals (USA) Inc.
Source: National Stock Exchange of India, BSE Limited, and the US Food and Drug Administration.
